ES2169691B1 - Trimeros de n-alquilglicina capaces de bloquear la respuesta a sustancias quimicas, estimulos termicos o mediadores de la inflamacion de receptores neuronales, y composiciones que los contienen. - Google Patents

Trimeros de n-alquilglicina capaces de bloquear la respuesta a sustancias quimicas, estimulos termicos o mediadores de la inflamacion de receptores neuronales, y composiciones que los contienen.

Info

Publication number
ES2169691B1
ES2169691B1 ES200002458A ES200002458A ES2169691B1 ES 2169691 B1 ES2169691 B1 ES 2169691B1 ES 200002458 A ES200002458 A ES 200002458A ES 200002458 A ES200002458 A ES 200002458A ES 2169691 B1 ES2169691 B1 ES 2169691B1
Authority
ES
Spain
Prior art keywords
ethyl
mediators
inflammation
response
compositions containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200002458A
Other languages
English (en)
Other versions
ES2169691A1 (es
Inventor
Montiel Antonio Ferrer
Cases Rosa Planells
Martinez Carolina Garcia
Ros Jose Manuel Gonzalez
Fernandez Jaime M Merino
Martinez Carlos Belmonte
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DiverDrugs SL
Original Assignee
DiverDrugs SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES200002458A priority Critical patent/ES2169691B1/es
Application filed by DiverDrugs SL filed Critical DiverDrugs SL
Priority to EP01974349A priority patent/EP1338605A1/en
Priority to KR10-2003-7005128A priority patent/KR20030048056A/ko
Priority to MXPA03003158A priority patent/MXPA03003158A/es
Priority to PCT/ES2001/000384 priority patent/WO2002030956A1/es
Priority to CA002425520A priority patent/CA2425520A1/en
Priority to BR0114802-8A priority patent/BR0114802A/pt
Priority to AU2001293882A priority patent/AU2001293882A1/en
Priority to JP2002534341A priority patent/JP2004511491A/ja
Priority to US10/398,947 priority patent/US20040033958A1/en
Publication of ES2169691A1 publication Critical patent/ES2169691A1/es
Application granted granted Critical
Publication of ES2169691B1 publication Critical patent/ES2169691B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Trímeros de N-alquilglicina capaces de bloquear la respuesta a sustancias químicas, estímulos térmicos o mediadores de la inflamación de receptores neuronales, y composiciones que los contienen. Los trímeros de N-alquilglicina (I), donde R{sub,1} es 2-(2,4-diclorofenil)etilo, 3-metil-butilo, 2- (metilcarbonilamino)etilo, 2-(N-imidazolil)etilo o 3-(N,N- dimetilamino)propilo; R{sub,2} es 2-(2,4-diclorofenil)etilo, 2- (4-metoxifenil)etilo, 3,3-difenilpropilo o 3- (N,N-dietilamino) propilo; y R{sub,3} es N,N-dietil-aminopropilo, 3,3-difenil- propilo o 2-[2-(N-metil)pirrolidil] etilo, son capaces de bloquear los canales iónicos que se activan por sustancias químicas exógenas, por estímulos térmicos o por mediadores de la inflamación, tales como los nociceptores VR1 y los receptores ionotrópicos de glutamato, y son útiles para tratar trastornos mediados por la actividad de dichos receptores.
ES200002458A 2000-10-11 2000-10-11 Trimeros de n-alquilglicina capaces de bloquear la respuesta a sustancias quimicas, estimulos termicos o mediadores de la inflamacion de receptores neuronales, y composiciones que los contienen. Expired - Fee Related ES2169691B1 (es)

Priority Applications (10)

Application Number Priority Date Filing Date Title
ES200002458A ES2169691B1 (es) 2000-10-11 2000-10-11 Trimeros de n-alquilglicina capaces de bloquear la respuesta a sustancias quimicas, estimulos termicos o mediadores de la inflamacion de receptores neuronales, y composiciones que los contienen.
JP2002534341A JP2004511491A (ja) 2000-10-11 2001-10-11 化学物質、熱刺激またはニューロン受容体炎症のメディエーターに対する応答を遮断することが可能なｎ−アルキルグリシントリマーおよび該トリマーを含有する組成物
MXPA03003158A MXPA03003158A (es) 2000-10-11 2001-10-11 Trimeros de n-alquilglicina capaces de bloquear la respuesta a sustancias quimicas, estimulos termicos o mediadores de la inflamacion de receptores neuronales; y composiciones que los contienen .
PCT/ES2001/000384 WO2002030956A1 (es) 2000-10-11 2001-10-11 Trimeros de n-alquilglicina capaces de bloquear la respuesta a sustancias quimicas, estimulos termicos o mediadores de la inflamacion de receptores neuronales, y composiciones que los contienen
CA002425520A CA2425520A1 (en) 2000-10-11 2001-10-11 N-alkylglycine trimeres capable of blocking the response to chemical substances, heat stimuli or mediators of neuronal receptor inflammation and compositions containing said trimeres
BR0114802-8A BR0114802A (pt) 2000-10-11 2001-10-11 Trìmeros de n-alquilglicina capazes de bloquear a substáncias quìmicas, estìmulos térmicos ou mediadores da inflamação de receptores neuronais, e composições que os contêm
EP01974349A EP1338605A1 (en) 2000-10-11 2001-10-11 N-alkylglycine trimeres capable of blocking the response to chemical substances, heat stimuli or mediators of neuronal receptor inflammation and compositions containing said trimeres
KR10-2003-7005128A KR20030048056A (ko) 2000-10-11 2001-10-11 화학 물질, 열 자극 또는 신경 수용체 염증의 매개체들에대한 반응을 차단하는 능력을 갖는 ｎ-알킬글리신 트리머및 그를 포함하는 조성물
US10/398,947 US20040033958A1 (en) 2000-10-11 2001-10-11 N-alkylglycine trimeres capable of blocking the response to chemical substances, heat stimuli or mediators of neuronal receptor inflammation and compositions containing said trimeres
AU2001293882A AU2001293882A1 (en) 2000-10-11 2001-10-11 N-alkylglycine trimeres capable of blocking the response to chemical substances,heat stimuli or mediators of neuronal receptor inflammation and compositions containing said trimeres

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200002458A ES2169691B1 (es) 2000-10-11 2000-10-11 Trimeros de n-alquilglicina capaces de bloquear la respuesta a sustancias quimicas, estimulos termicos o mediadores de la inflamacion de receptores neuronales, y composiciones que los contienen.

Publications (2)

Publication Number Publication Date
ES2169691A1 ES2169691A1 (es) 2002-07-01
ES2169691B1 true ES2169691B1 (es) 2004-03-16

Family

ID=8495245

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200002458A Expired - Fee Related ES2169691B1 (es) 2000-10-11 2000-10-11 Trimeros de n-alquilglicina capaces de bloquear la respuesta a sustancias quimicas, estimulos termicos o mediadores de la inflamacion de receptores neuronales, y composiciones que los contienen.

Country Status (10)

Country Link
US (1) US20040033958A1 (es)
EP (1) EP1338605A1 (es)
JP (1) JP2004511491A (es)
KR (1) KR20030048056A (es)
AU (1) AU2001293882A1 (es)
BR (1) BR0114802A (es)
CA (1) CA2425520A1 (es)
ES (1) ES2169691B1 (es)
MX (1) MXPA03003158A (es)
WO (1) WO2002030956A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2195787B1 (es) 2002-05-20 2005-06-01 Diverdrugs, S.L. Compuestos capaces de bloquear la respuesta a sustancias quimicas o estimulos termicos o mediadores de la inflamacion de los nociceptores, un metodo para su obtencion y composiciones que los continen.
AU2004230207A1 (en) * 2003-04-15 2004-10-28 Merck Patent Gmbh Identification of N-alkylglycine trimers for induction of apoptosis
HUE029393T2 (en) * 2010-08-31 2017-03-28 Bionure Farma S L Neurotrophin receptor agonists and their use as medicaments
WO2012098281A2 (es) 2011-01-19 2012-07-26 Universidad Miguel Hernández De Elche Péptidos moduladores de receptores trp y sus usos
WO2017066454A2 (en) 2015-10-14 2017-04-20 X-Therma, Inc. Compositions and methods for reducing ice crystal formation
CN111563445A (zh) * 2020-04-30 2020-08-21 徐宇轩 一种基于卷积神经网络的显微镜下岩性识别方法
DE102022104759A1 (de) 2022-02-28 2023-08-31 SCi Kontor GmbH Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747458A (en) * 1995-06-07 1998-05-05 Chiron Corporation Urokinase receptor ligands

Also Published As

Publication number Publication date
JP2004511491A (ja) 2004-04-15
EP1338605A1 (en) 2003-08-27
BR0114802A (pt) 2003-09-23
KR20030048056A (ko) 2003-06-18
US20040033958A1 (en) 2004-02-19
WO2002030956A1 (es) 2002-04-18
MXPA03003158A (es) 2004-12-06
CA2425520A1 (en) 2002-04-18
ES2169691A1 (es) 2002-07-01
AU2001293882A1 (en) 2002-04-22

Similar Documents

Publication Publication Date Title
Varga et al. Effects of the novel TRPV1 receptor antagonist SB366791 in vitro and in vivo in the rat
Reiner et al. Mechanisms of antihistamine-induced sedation in the human brain: H1 receptor activation reduces a background leakage potassium current
Cao Voltage-gated calcium channels and pain
GT199800021A (es) Utilizacion de antagonistas de los receptores de canabinoides centrales para la preparacion de medicamentos.
BR0009830A (pt) Composições para cuidados com a pele contendo uma combinação de substâncias ativas para cuidados com a pele
PE20010645A1 (es) Compuestos espiro como antagonistas de los receptores del neuropeptido y
DE69833451D1 (de) Behandlung der schizophrenie mit ampakinen und neuroleptika
DK1196397T3 (da) Metabotrope glutamatreceptorantagonister og anvendelse deraf til behandling af sygdomme i centralnervesystemet
ES2169691B1 (es) Trimeros de n-alquilglicina capaces de bloquear la respuesta a sustancias quimicas, estimulos termicos o mediadores de la inflamacion de receptores neuronales, y composiciones que los contienen.
AR007118A1 (es) 4(3h)-quinazolinonas 2,3 disustituidas y composiciones farmaceuticas que las contienen
ECSP941156A (es) 3 bencilaminometil piperidinas substituidas con heteroarilamino y heteroarilsulfonamido y compuestos afines
NO985977L (no) Spiro-piperidinderivater og deres anvendelse som terapeutiske midler
DK1254899T3 (da) Piperazinderivater og deres anvendelse som anti-inflammatoriske midler
AR002459A1 (es) Antagonistas de vasopresina de benzacepina triciclicos, una composicion farmaceutica que los contiene, un metodo para tratar enfermedades y unprocedimiento para su preparacion.
PA8550101A1 (es) Derivados de benzamida tiazol y composiciones farmacéuticas para inhibir la proliferación de células, y métodos para su utilización
BR9507073A (pt) Composto processos para preparar o mesmo e para tratar uma doença no sistema nervoso central composiçao farmacêutica e uso do composto
CO4700426A1 (es) Ligandos especificos del neuropeptido y1
González et al. Methamphetamine blunts Ca2+ currents and excitatory synaptic transmission through D 1/5 receptor‐mediated mechanisms in the mouse medial prefrontal cortex
ES2150671T3 (es) Compuesto de bencimidazol y su utilizacion como moduladores del complejo de receptores gaba-a.
NO994850L (no) Farmakologiske midler
GT199800135A (es) 2 - aminopiridinas con sustituyentes alcoxi ramificados.
UY27232A1 (es) Nuevos compuestos de dihidropirimidina ciano substituidos y su uso para tratar padecimientos
ATE381533T1 (de) Pharmazeutisch wirksame verbindungen und methoden zu ihrer anwendung
PE20020411A1 (es) Compuestos derivados de la triptamina y sus analogos que interactuan con el sistema melatoninergico
ATE498619T1 (de) Azabicycloä3.1.0ühexanderivate als modulatoren von dopamin-d3-rezeptoren

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2169691B1

Country of ref document: ES

FD1A Patent lapsed

Effective date: 20100312